<DOC>
	<DOCNO>NCT02561585</DOCNO>
	<brief_summary>This clinical trial attempt investigate efficacy safety LEO 124249 treatment alopecia areata molecular disease mechanism biomarkers .</brief_summary>
	<brief_title>LEO 124249 Ointment Treatment Alopecia Areata</brief_title>
	<detailed_description>The objective clinical trial compare efficacy twice-daily topical LEO 124249 30 mg/g ointment LEO 124249 ointment vehicle 12 week treatment hair loss subject alopecia areata , evaluate safety treatment , evaluate hair regrowth , determine subject quality life , explore disease mechanism biomarkers .</detailed_description>
	<mesh_term>Alopecia</mesh_term>
	<mesh_term>Alopecia Areata</mesh_term>
	<criteria>Subjects must sign date informed consent receive verbal write information clinical trial . Subjects unequivocal clinical diagnosis moderate severe scalp alopecia areata ( patch type , totalis , universalis ) , determine ( sub ) investigator , affect minimum 30 % scalp area Visit 1 ( Screening ) Visit 2 ( Day 1 , baseline ) . Minimum 6 month duration hair loss Visit 1 ( Screening ) . No upper limit time limit . Subject must accept cut hair treat scalp area trial . Females pregnant breast feeding . Current sign spontaneous hair regrowth . Diffuse type alopecia areata . Coexisting moderate severe androgenic alopecia ( NorwoodHamilton stage IVVI Ludwig stage II III ) Subjects change expect change medication thyroid disease within 6 month Visit 1 ( screen ) trial . Systemic treatment immunosuppressive drug ( e.g . methotrexate , cyclosporine , azathioprine ) , chloroquin derivative , corticosteroid , systemic therapy opinion investigator could affect hair regrowth , within 6 week prior randomization ( inhaled intranasal steroid correspond 1 mg prednisone asthma rhinitis may use ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>